Global Signature Molecule Market Trends and Forecast to 2026The Global Signature Molecule Market Report is an extensive and comprehensive document comprising details on business strategies, qualitative and quantitative analysis of the market on global and regional levels.The report strives to offer a deeper understanding of the Signature Molecule industry by offering an extensive overview of the competitive landscape and regional segmentation.The report assesses the impact of various market factors on the growth of the Signature Molecule Market in key regions and across key segments.It offers a detailed insight into the impact of COVID-19 on the industry at a regional level and industry level.Furthermore, the report provides a comprehensive analysis of the impact of the COVID-19 crisis on the market.Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1422The report provides a panoramic overview of the Signature Molecule Market’s competition landscape through a thorough profiling of the companies with regards to their market share, recent developments and advancements, gross margins, business expansion plans, product portfolio, production and manufacturing capacity, financial standing, and revenue contribution.Top Players Covered in the Report Include:Abbott Laboratories, Agilent Technologies, Merck & Co Inc., Novartis, Pfizer, Qiagen N.V and Thermo Fischer Scientific IncRequest a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1422Furthermore, the report segments the market on the basis of types, applications, and key geographical regions.Biomolecule Type (Revenue, USD Million; 2016–2026)Genetic BiomarkersEpigenetic BiomarkersProteomic BiomarkersGlycoprotein BiomarkersDisease Type (Revenue, USD Million; 2016–2026)Breast CancerBlood CancerLung CancerCervical CancerColorectal CancerMelanomaOvarian CancerLiver CancerStomach CancerProfiling Technologies (Revenue, USD Million; 2016–2026)Imaging technologiesUltrasoundComputed Technology (CT)Magnetic Resource Imaging (MRI)Positron Emission Tomography (PET)Omic TechnologiesProteomicsGenomicsOthersCytogenetics-Based TestsImmunoassaysBioinformaticsApplication (Revenue, USD Million; 2016–2026)Risk AssessmentPrognosticsDisease DiagnosisPersonalised MedicineDrug Discovery and DevelopmentMethod (Revenue, USD Million; 2016–2026)Sample PreparationAssay DevelopmentBiomarkers and TestingRegional Segmentation:The Global Signature Molecule Market is analyzed across the key geographical regions where the market has already established its presence.These regions include key areas such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.Further, each region is extensively analyzed on the country level for the production and consumption ratio, import/export, supply and demand dynamics, trends, developments, revenue contribution, market share in terms of volume and value, and the presence of the prominent players in each region.The extensive analysis of the key geographical regions include:North America (U.S., Canada)Europe (U.K., Italy, Germany, France, Rest of EU)Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)Latin America (Chile, Brazil, Argentina, Rest of Latin America)Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)To know more about the report, visit @ https://www.reportsanddata.com/report-detail/cancer-biomarkers-marketKey Points Covered by the Report:The report offers a comprehensive overview of the global Signature Molecule Market along with the idea about the content of the research studyThe report offers strategic recommendations to both established and novice players to aid in fortifying their presenceThe report presents insightful data to the companies to help them gain maximum returns on their investment and formulate new investment strategiesIt provides a comprehensive overview of the competitive landscape to offer a competitive edge to the readersThe report covers an extensive regional analysis to impart a better understanding of the spread of the market in key geographies of the worldIn-depth analysis of the current and emerging market trends and drivers and restraintsAn 8-year comprehensive forecast for the Signature Molecule Market on the global and regional scaleThorough SWOT analysis and Porter’s Five Forces analysisBrowse Related Reports –Refrigerants Market Future Growth with Technology and Outlook 2020 to 2027 – https://www.reportsanddata.com/report-detail/refrigerants-marketWater Quality Monitoring Equipment Market 2027: Regional Trend & Growth Projections – https://www.reportsanddata.com/report-detail/water-quality-monitoring-equipment-marketThank you for reading our report.
Immunoassay Market Research by Product (Reagents and Kits, Analyzers/Instruments, Software and Services), Technology [Radioimmunoassay (RIA), Enzyme-linked Immunosorbent Assay (ELISA), Enzyme-linked Fluorescent Assay (ELFA), Chemiluminescence Immunoassay (CLIA), Rapid Test, Others], Indication (Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Diseases, Autoimmune Diseases, Others), End User and Region – Forecast till 2025Immunoassay Market Overview:Immunoassay uses a small antibody or an antigen to determine the presence of a small molecule in a solution.Often the process requires a calibrator for a better analysis.Global Immunoassay Market, as reported in the latest study of the market by Market Research Future (MRFR), is expecting a Growth by 8.5% CAGR to reach USD 771.1 million during the forecast period (2017-2023).Also Read https://www.openpr.com/news/1112861/immunoassay-market-overview-along-with-competitive-landscape-company-profiles-with-product-details-and-competitors-and-forecast-2023.htmlGrowing biotechnology and pharmaceutical sectors, across the globe, is all set to provide stimulants for the market growth.But the complex procedure of the test and lack of specificity in the results can be a market deterrent.Competitive Landscape:Major players, as reported by MRFR in the global immunoassay treatment market areAbbott LaboratoriesBeckman Coulter Inc.AlereArlington ScientificRadiometerBio-Rad LaboratoriesBioMerieux Inc.DiaSorinDiamedixFujirebio USDynex TechnologiesGold Standard DiagnosticsHycor BiomedicalInova DiagnosticsRandox ToxicologyOrtho-Clinical DiagnosticsHoffmann-La Roche Ltd.ThermoFisher ScientificSiemens HealthineersWako DiagnosticsTOSOH BioscienceShenzhen New Industries Biomedical Engineering Co.Ltd.Sysmex Corporationand others.Immunoassay Market-Segmentation:MRFR segments the global immunoassay market by product and service, type, and end-user.Based on the product and service, the immunoassay market can be segmented into reagents and kits, analyzers, and software and services.The reagents and kits segment includes Enzyme-Linked Immunosorbent Assay (ELISA) reagents & kits, elispot reagents & kits, western blot reagents & kits, rapid test reagents & kits, RIA reagents & kits, and PCR reagents & kits.The analyzers segment can be segmented into portable analyzers and benchtop analyzers.Based on the type, the immunoassay market can be segmented into Enzyme Immunoassays (EIA) or Enzyme-Linked Immunosorbent Assays (ELISA), Radioimmunoassay (RIA), Fluoroimmunoassay (FIA), Counting Immunoassay (CIA), and Chemiluminescence immunoassay (CLIA).Based on the application, the immunoassay market can be segmented into infectious diseases, autoimmune disorders, oncology, neonatal screening, toxicology, hematology & blood screening, cardiology, bone & mineral disorders, and others.Based on the end-user, the immunoassay market includes biotechnology companies, diagnostic laboratories, research & academic laboratories, hospitals & clinics, pharmaceutical companies, and others.Regional AnalysisThe global immunoassay market has been categorized on the basis of region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
1
Global Biomarkers Market: SnapshotThe global market for biomarkers is gaining traction from a number of factors, including increasing diagnosis applications for companion diagnostics and personalized medicine, rapidly growing number of Cros, reducing cost of clinical trials in various emerging economies, high prevalence of cancer, increasing investment on research and development by biotechnology and pharmaceutical companies, and new initiatives regarding biomarker research.On the other hand, the biomarkers market is facing challenge from high capital investments, low cost-benefit ratio with total investment, technical issues pertaining to sample collection and storage, and poorly suited regulatory and reimbursement systems.Nevertheless, vastly populated emerging economies in Asia Pacific such as India and China are expected to open new revenue avenues for the companies operating in the biomarkers market, provided they can prove the clinical validity of the tests.Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=520Based on product, the global biomarkers market can be segmented into consumables, software, and service.On the basis of disease indication, the global biomarkers market can be classified into cancer, neurological disorders, cardiovascular diseases, immunology, and others such as urinal diseases, renal disorders, and diabetes.Also known as a molecular marker or signature molecule, biomarkers are found in blood, other body fluids, and tissue.Extensively used to see the body’s response to a particular treatment for a disease or condition, biomarkers assist medical professionals to take effective clinical decisions and help in diagnosing the health of patients.
The latest trending report Global Generic Injectables Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 offered by DecisionDatabases.com is an informative study covering the market with detailed analysis.The report will assist reader with better understanding and decision making.The Generic Injectables market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.The global Generic Injectables market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 5.0%% in the forecast period of 2020 to 2025 and will expected to reach USD 31850 million by 2025, from USD 26160 million in 2019.Final Report will cover the impact of COVID-19 on this industry.Browse the complete report and table of contents @ https://www.decisiondatabases.com/ip/42327-generic-injectables-industry-market-reportThe major players covered in Generic Injectables are:PfizerLupin PharmaceuticalsFreseniusSandoz InternationalHikma PharmaceuticalsBaxterBioconTeva PharmaceuticalMylanSanofiBy Type, Generic Injectables market has been segmented into:Large Molecule Injectables (Biosimilars)Small Molecule InjectablesBy Application, Generic Injectables has been segmented into: OncologyInfectious DiseasesCardiologyDiabetesImmunologyOthersThe report offers in-depth assessment of the growth and other aspects of the Generic Injectables market in important countries (regions), including:North America (United States, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, etc.)Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)Download Free Sample Report of Global Generic Injectables Market @ https://www.decisiondatabases.com/contact/download-sample-42327The content of the study subjects, includes a total of 15 chapters:Chapter 1, to describe Generic Injectables product scope, market overview, market opportunities, market driving force and market risks.Chapter 2, to profile the top manufacturers of Generic Injectables, with price, sales, revenue and global market share of Generic Injectables in 2018 and 2019.Chapter 3, the Generic Injectables competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.Chapter 4, the Generic Injectables breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.Chapter 12, Generic Injectables market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.Chapter 13, 14 and 15, to describe Generic Injectables sales channel, distributors, customers, research findings and conclusion, appendix and data source.Purchase the complete Global Generic Injectables Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-42327Other Reports by DecisionDatabases.com:  Global Injectable Drugs Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Global Injectable Anticoagulants Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Global Injectable Bags Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024About-Us:DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics.DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains.Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors.We provide intellectual, precise and meaningful data at a lightning speed.For more details:DecisionDatabases.comE-Mail: [email protected]: +91 9028057900Web: https://www.decisiondatabases.com/News Source - https://www.industrynewsengine.com/2020/11/30/generic-injectables-market-report-till-2025-global-manufacturers-analysis/
The global human microbiome therapeutics market size is expected to reach USD 1,544.6 million by 2027 according to a new study by Polaris Market Research.The report “Human Microbiome Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Product (Probiotics, Prebiotics, Medical Foods, and Prescription Drugs); By Therapeutic Area (Autoimmune Disorders, Dental Disorders, Digestive and Gastrointestinal Disorders, Dermatological Disorders, Infectious Disease, Metabolic Disorders, Oncology, and Others); By Indication (Acne Vulgaris, Atopic Dermatitis, Clostridium difficile Infection, Colorectal Cancer, Diabetes, Inflammatory Bowel Disease (IBD), Lactose Intolerance, Lung Cancer, Non-alcoholic steatohepatitis (NASH), Obesity, and Coeliac Disease); By Approach (Small Molecule Therapies, Single Strain Whole Bacteria, Microbial Consortia, Genetically Modified Single Strain Bacteria, Phage Cocktail, and Microbial Ecosystems), By Regions; Segment Forecast, 2020 –2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.Microbiome refers to the residing micro-organisms genomes in the human body, particularly in the gut.The human body comprises more than 100 trillion microbes and around 2 million microbe genomes.These microbiota plays a significant role in the body’s physiological functions and includes viruses, bacteria, and fungi.The majority of these are strict anaerobes, with fungi and archaebacteria comprising less than 1 per cent of the total population.Request for sample copy of this report @https://www.polarismarketresearch.com/industry-analysis/human-microbiome-therapeutics-market/request-for-sampleThe global market is driven by an increased focus on microbiome based early diagnosis of diseases, increase in the prevalence of diseases due to dysbiosis, rising collaborations, and strongly funded government backed microbiome research projects.The aim is to create the largest human microbiome database from analyzing more than one million samples gathered from reproductive tract, gut, skin, and other organs in the next few years.Market participants such as Enterome Bioscience, Biotagenics, Seres Therapeutics, Oxidien Pharmaceuticals, LLC, BoobyBiome, 4D Pharma PLC, UBiome, Carbiotix, E.I.
Summary – A new market study, “Global and Chinese Pharmaceutical Grade Marijuana Industry, 2017 Market Research Report”has been featured on WiseGuyReports.Also Read : - https://www.whatech.com/market-research/medical/660797-marijuana-market-is-segmented-by-type-of-molecule-pharmaceuticals-and-biopharmaceuticals-drug-class-sales-channel-and-geographyThe 'Global and Chinese Pharmaceutical Grade Marijuana Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Pharmaceutical Grade Marijuana industry with a focus on the Chinese market.The report provides key statistics on the market status of the Pharmaceutical Grade Marijuana manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology.In this part, the report presents the company profile, product specifications, capacity, production value, and 2012-2017 market shares for each company.Through the statistical analysis, the report depicts the global and Chinese total market of Pharmaceutical Grade Marijuana industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.The report then estimates 2017-2022 market development trends of Pharmaceutical Grade Marijuana industry.Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.
4
Summary -   A new market study, titled “Global Isomaltulose Market Professional Survey Report 2019” has been featured on Wise Guy Reports.Isomaltulose is a sucrose isomer, is a reducing disaccharide, composed of a fructose and glucose molecule joined together by a 1, 6- glycosidic bond.Isomaltulose occurs at low levels in honey as well as in sugar cane and sugar beet extract naturally.ALSO READ: https://icrowdnewswire.com/2019/11/06/isomaltulose-market-segmentation-application-technology-market-analysis-research-report-2025/ The global isomaltulose market driving factor is the increasing demand for non-carcinogenic sugar for the manufacture of food and healthcare products.Isomaltulose is extensively used for the production of food products such as candies, chocolates, cereals, sports and energy drinks along with health supplements.The global Isomaltulose market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.This report focuses on Isomaltulose volume and value at global level, regional level and company level.From a global perspective, this report represents overall Isomaltulose market size by analyzing historical data and future prospect.Regionally, this report categorizes the production, apparent consumption, export and import of Isomaltulose in North America, Europe, China, Japan, Southeast Asia and India.For each manufacturer covered, this report analyzes their Isomaltulose manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
Summary - A new market study, titled “Global Injectable Drugs Market 2017-2021 ” has been featured on WiseGuyReports.Injectable drugs are directly infused into the body with the help of a syringe and a hollow needle.The market encompasses drugs that are used for the prevention and cure of various diseases, and are mainly of two types, namely, biologics and small molecule drugsALSO READ: https://www.newsmaker.com.au/news/379725/injectable-drugs-industry-treatment-outlook-analysis-research-review-to-2025#.X4V5_NAzaM8Technavio’s analysts forecast the global injectable drugs market to grow at a CAGR of 8.21% during the period 2017-2021.Covered in this report The report covers the present scenario and the growth prospects of the global injectable drugs market for 2017-2021.To calculate the market size, the report considers the sales of vaccines, branded, generic, and off-label drugs.The market is divided into the following segments based on geography: • Americas • APAC • EMEATechnavio's report, Global Injectable Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts.The report covers the market landscape and its growth prospects over the coming years.The report also includes a discussion of the key vendors operating in this market.Key vendors • AbbVie • F. Hoffmann-La Roche • GlaxoSmithKline • SanofiOther prominent vendors • Bayer • Bristol-Myers Squibb • Merck • Takeda Pharmaceutical • Teva PharmaceuticalMarket driver • Escalation in demand for self-injection devices • For a full, detailed list, view our reportMarket challenge • High cost of production • For a full, detailed list, view our reportMarket trend • Increase in industry-academia collaboration • For a full, detailed list, view our reportKey questions answered in this report • What will the market size be in 2020 and what will the growth rate be?• What are the market opportunities and threats faced by the key vendors?
1
Download Sample Table of Content PDF of COVID-19/CoronaVirus Impact Analysis of AI in drug discovery market 2020 @https://www.marketresearchfuture.com/sample_request/9393 According to Market Research Future (MRFR), the global AI in drug discovery market is poised to create a valuation of USD 2,015.1 MN by 2025, registering a massive 40.8% CAGR throughout the predicted years (2019 – 2025).AI integration minimizes the risk of adverse reactions during trials, reduces the drug discovery timeframe, and, most importantly, reduces drug development costs.Moreover, rising numbers of start-ups operating in the AI spectrum drug discovery foster market growth.Also, the lack of adequate infrastructure in low economic countries obstructs the growth of the market.Major Players: Players leading the global AI in drug discovery market include Microsoft Corporation, IBM Corporation, Alphabet Inc., Atomwise, Inc., Deep Genomics, Cloud Pharmaceuticals, Inc., Insilico Medicine, BenevolentAI, Exscientia, Cyclica, Bioage, Numerate, Numedii, Inc., Envisagenics, Twoxar, Incorporated, Owkin, Inc., Xtalpi, Inc., Verge Genomics, and Berg LLC, among others.By End-User : Pharmaceutical & Biotechnology Companies, Research Centers and Academic & Government Institutes, Contract Research Organizations, and others.
Anti-Venom Market Driven by Enhancing Regulatory FrameworkThe recent report by Market Research Future (MRFR) predicts the global anti-venom market value will be expanding with a healthy CAGR of 6.5% over the forecast period (2017–2023).Biotechnology, as well as the healthcare industry, is noting a considerable demand from developing nations globally.Moreover, violation of forest lands for housing and agricultural needs has gotten humans close to poisonous animals and insects, thereby increasing the prevalence of venomous bites.In addition, the prevalence of snake bites, scorpion bites, as well as other animal or insect bites like fish stings is an additional factor playing a major role in the anti-venom market growth.Various research and development (R) activities taking place continuously that provide advanced drugs and standard treatment for poisonous insect bite further uplifts the market position of anti-venom.This is yet another driver responsible for the growth of the global anti-venoms market.In contrast, the high cost of anti-venom due to the high production cost in a few regions could hamper the growth of the anti-venom market.However, the rapid development of the economic conditions around the world is creating massive opportunities for the expansion of the anti-venom market.The contribution of the developing countries of Asia Pacific as well as the Middle East coupled with the growing population and increasing capita income will foster the growth of the market.Segmentation The global anti-venom market is segmented on the basis of type, type of species, mode of action, product type, and end user.The global anti-venom market, by type, is categorized into polyvalent heterologous antivenom, monovalent heterologous antivenom, homologous antivenom, and small molecule anti-toxins.By species type, the global anti-venom market is segmented into snakes, scorpions, spiders, and others.
The COVID-19 pandemic has severely impaired the overall pharmaceutical supply chain, mostly owing to the absence of workers at manufacturing sites and restrictions imposed on distribution networks.In this context, continuous manufacturing offers a viable solution given the fact that continuous processes are largely automated.In fact, the FDA (and other regulatory bodies) have also expressed interest in advocating a shift to the use of advanced manufacturing technologies, such as continuous manufacturing.To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this link The USD 1.9 billion (by 2030) financial opportunity within the continuous manufacturing market has been analyzed across the following segments:Purpose of ManufacturingIn-HouseContract service Scale of OperationCommercialPreclinical / Clinical Type of Continuous Manufacturing related ServiceAPI ManufacturingEnd Product manufacturing Type of Drug MoleculeBiologicSmall Molecule Type of dosage formSolidLiquid Key Geographical RegionsNorth AmericaEuropeAsia Pacific The Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030 report features the following companies, which we identified to be key players in this domain: AbbVie Contract ManufacturingAjinomoto Bio-Pharma ServicesAlmacBoehringer Ingelheim BioXcellenceCambrexCordonPharmaHovioneKanekaLonzaPatheonSK biotek Table of Contents  Preface 2.Executive Summary Introduction Market Landscape Companies with Expertise in Continuous Manufacturing in North America: Profiles Companies with Expertise in Continuous Manufacturing in Europe: Profiles Companies with Expertise in Continuous Manufacturing in Asia-Pacific: Profiles Recent Partnerships and Collaborations Recent Expansions Capacity Analysis Academic Grant Analysis Patent Analysis Initiatives of Companies with In-House Continuous Manufacturing Capabilities Case Study: Modular Facilities in pharmaceutical / Biotechnological Industry  Case Study: Technology and Equipment Providers  Case Study: Roadmap for the Adoption of Continuous Manufacturing Processes  Market Forecast and Opportunity Analysis  Conclusion  Executive Insights  Appendix 1: Tabulated Data  Appendix 2: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html Contact DetailsGaurav Chaudhary+1 (415) 800 [email protected]  
1
Roots Analysis has done a detailed study on Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030, covering key aspects of the industry and identifying future growth opportunities.To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this link Key Market Insights Eminent representatives from prominent contract service provider companies / organizations are both optimistic and cautious regarding the rising interest in continuous flow technologies, and its adoptionOver 60 companies across the globe claim to manufacture drug products / drug substances using the continuous manufacturing technique, either for in-house requirements or for contract service engagementsThe market landscape features the presence of several well-established players, most of which claim to manufacture small molecules via the continuous technique, and are based in the developed geographiesCompanies have established continuous drug manufacturing facilities for diverse types of dosage forms in various geographies; Europe and North America have emerged as the key hubs for these facilitiesSeveral patents have been filed / granted specifically related to continuous manufacturing of pharmaceutical substances, both industry and non-industry players are actively involved in such effortsOrganizations have also extended financial support to aid the research efforts being put by various stakeholders in this domain; the current focus is on investigation of continuous manufacturing technologiesOver time, there has been a lot of activity in this arena, including the establishment of several partnerships and investments in capability and capacity expansions and new facilities worldwideMost of the continuous manufacturing capacity belongs to established companies (in-house manufacturers and CMOs), accounting for over 70% of the available capacity across various geographiesInvolvement of various other stakeholders including continuous equipment providers and modular facility providers is likely to revolutionize the overall manufacturing domainAs the adoption of continuous manufacturing technologies increases, the market is likely to witness significant growth; in the short term, majority of service-based revenues is likely to come from drug product related projects For more information, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html Table of Contents TABLE OF CONTENTS  PREFACE 1.1.Analysis by Location of Continuous Manufacturing Facilities4.2.7.Global, Continuous Manufacturing Capacity for Small Molecule APIs10.3.1.Interview Transcript: Andrea Adamo, Founder and Chief Executive Officer  19.3.Interview Transcript: Ian Houson, Technical Project Manager   APPENDIX 1: TABULATED DATA  APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS Contact DetailsGaurav Chaudhary+1 (415) 800 [email protected]
 To order this detailed 285+ page report, please visit this link Key Inclusions A detailed review of the overall landscape of companies, offering contract services for the manufacturing of antibodies, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number of manufacturing facilities and location of these facilities, type of antibody manufactured (monoclonal antibodies, bispecific antibodies and polyclonal antibodies), type of expression systems used (mammalian, microbial and others), fill / finish operations and affiliations to regulatory agencies.A competitiveness analysis of key players engaged in this domain, featuring an assessment based on their supplier strength (related to the experience of a contract manufacturer), and service strength (which takes into account the size of service portfolio and scale of operation).A benchmark analysis, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective (geography-based) peer groups.An analysis of the various partnerships pertaining to contract manufacturing of antibodies, which have been established since 2013, based on several parameters, such as the year of agreement, type of partnership, project scale and focus therapeutic area.An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective antibody manufacturing capabilities, over the period 2017-2019 (till October), taking into consideration parameters, such as year of expansion, type of expansion (capacity expansion, facility expansion and new facility), type of antibodies manufactured and location of manufacturing facility.An estimate of the overall, installed capacity for manufacturing antibodies based on data reported by industry stakeholders in the public domain; it highlights the distribution of available antibody production capacity on the basis of company size (small, mid-sized, large and very large firms), scale of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe, Asia).Informed estimates of the annual commercial and clinical demand for antibodies, based on various relevant parameters, such as target patient population, dosing frequency and dose strength.Elaborate profiles of the key industry players that offer contract manufacturing services at all scales of operation and have more than two manufacturing facilities.Each profile features a brief overview of the company, information on its service portfolio, details related to its manufacturing capabilities and facilities, and an informed future outlook.A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps and challenges involved in their respective manufacturing processes.A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:Type of AntibodiesMonoclonal AntibodiesBispecific AntibodiesADCsOthers Company SizeSmallMid-sizedLarge / Very Large Scale of OperationPreclinical / ClinicalCommercial Type of expression system usedMammalianMicrobial Key geographical regionsNorth AmericaEuropeAsia and RoW The report includes detailed transcripts of discussions held with the following experts:Dietmar Katinger (Chief Executive Officer, Polymun Scientific)David C Cunningham (Director, Corporate Development, Goodwin Biotechnology)Claire Otjes (Marketing Manager, Batavia Biosciences) To request sample pages, please visit this link Key Questions AnsweredWho are the leading CMOs engaged in the production of antibody-based therapeutics?What kind of partnership models are commonly adopted by stakeholders in this industry?What is the annual clinical and commercial demand for antibody-based products?What is the current installed capacity for manufacturing of antibodies?What are the various expansion initiatives undertaken by antibody CMOs?How is the current and future market opportunity likely to be distributed across key market segments?You may also be interested in the following titles:Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030Antibody Drug Conjugates (ADCs) - Linker and Conjugation Technologies Market, 2019-2030Antibody Drug Conjugates Market (5th Edition), 2019-2030 Contact UsGaurav Chaudhary+1 (415) 800 [email protected] 
Roots Analysis has done a detailed study on Antibody Contract Manufacturing Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.To order this 285+ page report, which features 100+ figures and 110+ tables, please visit this link Key Market Insights Several companies worldwide claim to possess the required expertise and infrastructure to offer contract manufacturing services for a variety of antibody-based products.The market landscape is highly fragmented, featuring the presence of both established players and new entrants; majority of antibody CMOs claim to operate as one stop shops and have presence across different regions.In recent years, a steady increase in partnership activity has been observed in this domain; a variety of deals have been inked related to antibodies for use across a number of different disease indications.At present, the installed, global antibody contract manufacturing capacity is estimated to be approximately 2.2 million liters, distributed across companies of all sizes worldwide.In order to enhance core competencies related to this field of research, CMOs are actively investing in upgrading existing infrastructure and expanding their respective manufacturing capacities.In fact, ongoing capability improvement efforts and facility upgrades have led to the establishment of industry benchmarks, which serve as a standard for new product development initiatives in this domain.Given that there are several antibody-based drug / therapy candidates being evaluated across various stages of development, the demand for such products is anticipated to rise significantly over the next decade.Antibody-based product developers are likely to continue to outsource their manufacturing operations in mid to long term, resulting in a multi-billion growth opportunity for contract service providers.Analysis by Location of Antibody Manufacturing Facilities4.2.6.Analysis by Regulatory Accreditations / Certifications4.2.9.Small Molecule Drugs and Biologics7.2.1.Analysis by Focus Therapeutic Area 9.3.7.
1
 The benefits of engaging a CMO or CDMO for antibody development and production extend beyond fulfilling the needs of small companies; access to new technologies and operational flexibility are attractive attributes to larger players as well Roots Analysis is pleased to announce the publication of its recent study, titled, “Antibody Contract Manufacturing Market, 2020-2030” report to its list of offerings.The report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of antibodies.The study also features a detailed analysis of key drivers and trends related to this evolving domain.In addition to other elements, the study includes:A detailed review of the overall landscape of companies, offering contract services for the manufacturing of antibodies.A competitiveness analysis of key players engaged in this domain, featuring an assessment based on their supplier strength and service strength.A benchmark analysis, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective (geography-based) peer groups.An analysis of the various partnerships pertaining to contract manufacturing of antibodies, which have been established since 2013.An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective antibody manufacturing capabilities, over the period 2017-2019 (till October).An estimate of the overall, installed capacity for manufacturing antibodies based on data reported by industry stakeholders in the public domain.Informed estimates of the annual commercial and clinical demand for antibodies, based on various relevant parameters, such as target patient population, dosing frequency and dose strength.Elaborate profiles of the key industry players that offer contract manufacturing services at all scales of operation and have more than two manufacturing facilities.A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps and challenges involved in their respective manufacturing processes.A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Type of AntibodiesMonoclonal AntibodiesBispecific AntibodiesADCsOthersCompany SizeSmallMid-sizedLarge / Very LargeScale of OperationPreclinical / ClinicalCommercialType of expression system usedMammalianMicrobialKey geographical regionsNorth AmericaEuropeAsia and RoW Transcripts of interviews held with the following senior level representatives of stakeholder companies:Dietmar Katinger (Chief Executive Officer, Polymun Scientific)David C Cunningham (Director, Corporate Development, Goodwin Biotechnology)Claire Otjes (Marketing Manager, Batavia Biosciences) Key companies covered in the reportAGC BiologicsAldevronAMRIBoehringer Ingelheim BioXcellenceEmergent BioSolutionsEurofins CDMOFUJIFILM Diosynth BiotechnologiesKBI BiopharmaLonzaNitto Avecia Pharma ServicesNovasepPierre FabreSamsung BioLogicsSynthonThermo Fisher Scientific For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html Other Recent OfferingsBispecific Antibody Therapeutics Market (4th Edition), 2019-2030Antibody Drug Conjugates (ADCs) - Linker and Conjugation Technologies Market, 2019-2030Antibody Drug Conjugates Market (5th Edition), 2019-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected]   
In the current market scenario, there is a growing demand for high throughput process development products.Growth in the global market is mainly driven by the increasing R spending, technological advancements in process development, growth in the biopharmaceutical industry, and growing pressure to lower the cost of manufacturing.However, factors such as the high cost of technology and equipment in this market and lack of adequate infrastructural facilities are restraining the growth of this market to a certain extent.The global high throughput process development market is expected to reach USD 415.5 Million in 2021 from USD 162.9 Million in 2015, at a CAGR of 14.4%.High Throughput Process Development Market by Product (Consumables (Minicolumn, Mini Bioreactor), Instruments), Services, Software, Molecule Type (mAB), Technology (Affinity Chromatography), End User (Biopharmaceutical) – Global Forecast to 2021The market is segmented on the basis of molecule type, end user, technology, product and service, and region.Based on molecule type, the market is classified into monoclonal antibodies and others (recombinant pro-insulin, polysaccharide vaccines, recombinant Green Fluorescent Protein (rGFP), fusion proteins, and interferon á-2a).The large share of this segment is attributed to the increasing adoption of targeted immunotherapy and rising number of US FDA-cleared therapeutic monoclonal antibodies.Based on end user, the market is categorized into biopharmaceutical companies, contract research organizations and academic research institutes.
1
The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare.The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago.Presently, a variety of other such chemical entities and molecular glues are under investigation.In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this link The USD 3.6 billion (by 2030) financial opportunity within the target protein degradation market has been analyzed across the following segments:Type of payment of licensing agreementsUpfront paymentsMilestone payments Type of protein degraderDegronimidsPROTACsSARDs / SERDsSpecific BET and DUB inhibitorsOther protein degraders Therapeutic areaNeurodegenerative disordersOncological disordersOther therapeutic areas Route of administrationOralIntravenousOther routes Key geographical regionNorth AmericaEuropeAsia-Pacific The Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 report features the following companies, which we identified to be key players in this domain:ArvinasCaptor TherapeuticsCelgeneGenetechKymera TherapeuticsMission TherapeuticsProgenraRadius HealthSanofi GenzymeZenopharm Table of Contents  Preface Executive Summary Introduction Current Market Landscape Company Profiles Clinical Trial Analysis KOL Analysis Publication Analysis Funding and Investment Analysis Partnerships and Collaborations Market Sizing and Opportunity Analysis Executive Insights  Concluding Remarks  Appendix 1: Tabulated Data  Appendix 2: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html Contact DetailsGaurav Chaudhary+1 (415) 800 [email protected]  
Roots Analysis has done a detailed study on Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this link Key Market InsightsMore than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications; in addition, there are 25+ technology platforms available for use in therapy development effortsThe pipeline features a variety of candidate drugs that target a wide range of disease-causing / associated proteins; majority of the existing drug candidates are designed for administration via non-invasive routesAlthough start-ups and mid-sized firms are spearheading the innovation, several big pharmaceutical companies are also engaged in this domainClose to 5,500 patients were estimated to have been enrolled in clinical trials worldwide, evaluating a number of relevant pre-marketing end points across various phases of developmentA number of prominent scientists from renowned universities have emerged as key opinion leaders, owing to their active involvement in clinical development effortsPublished scientific literature indicates that both industry and academic players have made equal contributions to the innovation in this field; the major focus of such studies is presently on PROTACsForeseeing a lucrative future, several private and public investors have invested over USD 3.5 billion across close to 100 instances of funding since 2014The increasing interest in this field is also reflected in recent partnership activity; most of these deals are focused on novel technology platforms, involving the active participation of both international and indigenous companiesShort term opportunity in this market is likely to be driven by licensing activity, depending on the capability of novel technologies to meet protein degrader design and development needsAs multiple mid-late stage drug candidates are approved for marketing, the long term opportunity is likely to be distributed across different types of protein degraders, target therapeutic areas and various global regions For more information please visit:https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html Table of Contents  PREFACE1.1.Selective Hormone Receptor Degraders (SHRDs)3.8.2.Targeted Protein Degradation-based Therapeutics and Technologies: Development Pipeline4.2.1.KOL Profile (Edward O’Mara)  PUBLICATION ANALYSIS8.1.Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurodegenerative Disorders, 2020-203011.3.4.2.
To order this 750+ page report, please visit this link Key InclusionsA detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment, employee size, geographical location of the CMO, number of manufacturing facilities, as well as the location of these facilities, GMP compliance, affiliations to regulatory agencies, type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion) and bioprocessing capacity.Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics.Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as a comprehensive future outlook.A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics; the analysis is based on various parameters, such as the year in which the agreement was signed, type of agreement, focus area and type of biologics.A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity.The analysis also depicts the relationship between important deal multiples based on the revenue, number of employees and experience of the acquired company.An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions.In addition, it provides information on the technology advancements related to biomanufacturing.A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research.The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), size of company (small-sized, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia and Middle East (China, India, Japan, South Korea and rest of the Asia and Middle East), and rest of the world (including Australia).An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on a various relevant parameter, such as target patient population, dosing frequency and dose strength of the abovementioned products.A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:Commonly Outsourced Business OperationsActive Pharmaceutical Ingredients (API)Finished Dosage Formulations (FDF)Types of Expression SystemMammalianMicrobialOthersCompany SizeSmallMid-SizedLarge and Very LargeScale of OperationPreclinicalClinicalCommercialKey Geographical Region North AmericaEuropeAsia-Pacific To request sample pages, please visit this link Key Questions AnsweredWho are the key manufacturers (industry / non-industry) of cell-based therapies, across the world?What is the global demand for biologics-based therapies?What are the major recent developments (such as partnerships and expansions) in this industry?What kind of partnership models are commonly adopted by stakeholders in this domain?What is the current, installed contract manufacturing capacity for biologics?How is the current and future market opportunity likely to be distributed across key market segments?
 Owing to the ever-increasing number of start-ups that are involved in R of novel biologics, there is an enormous opportunity for the CMOs in this domain.It is worth emphasizing that, since 2000, more than 115 new CMOs have been established in order to serve to the growing demand for novel biologics that have specific manufacturing requirements.The contemporary contract services market features a mix of large and small-sized CMOs and is characterized by multiple mergers and acquisitions as stakeholders strive to broaden their respective service portfolios.This has enabled several CMOs to offer end-to-end services, ranging from drug development, including preliminary R, preclinical and clinical trials, to commercial scale production and regulatory filings To order this 750+ page report, which features 200+ figures and 250+ tables, please visit this link The USD 13.9 billion (by 2030) financial opportunity within the biopharmaceutical manufacturing market has been analyzed across the following segments:Commonly Outsourced Business OperationsActive Pharmaceutical Ingredients (API)Finished Dosage Formulations (FDF)Types of Expression SystemMammalianMicrobialOthersCompany SizeSmallMid-SizedLarge and Very LargeScale of OperationPreclinicalClinicalCommercialKey Geographical Region North AmericaEuropeAsia-PacificRest of the World  The Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030. report features the following companies, which we identified to be key players in this domain: 3P BiopharmaceuticalsAbzenaAlbany Molecular ResearchBioVectraBioXcellence (Boehringer Ingelheim)CelonicCharles River LaboratoriesChemPartnerCobra BiologicsCordenPharmaCytovance BiologicsGE HealthcareGoodwin BiotechnologyGrand River Aseptic ManufacturingIDT BiologikaKBI BioPharmaKemwell BiopharmaLFB BiomanufacturingMeridian Life SciencePatheonPfizer CentreOnePX'TherapeuticsSamsung BioLogicsSanofi, CEPiAThermo Fisher ScientificVetter Pharma International  Table of Contents  Preface 2.Executive Summary Introduction Competitive Landscape Biopharmaceutical Contract Manufacturing in North America Biopharmaceutical Contract Manufacturing in Europe Biopharmaceutical Contract Manufacturing in Asia Pacific And the Rest of The World Biopharmaceutical Contract Manufacturing in Asia Pacific And the Rest of The World Case Study: Outsourcing of Biosimilars Case Study: Comparison of Small Molecule and Large Molecule Drugs / Therapies  Case Study on In-House Manufacturing Collaborations Recent Developments Capacity Analysis  Demand Analysis  Market Forecast  SWOT Analysis  Future of The Biopharmaceutical CMO Market  Survey Analysis  Interview Transcripts  Appendix 1: List of Non-Industry Players  Appendix 1: List of Non-Industry Players  Appendix 3: List of Companies and Organizations To purchase a copy, please visit https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html Contact Details Gaurav Chaudhary+1 (415) 800 [email protected]    
More

Top